A/Prof. Olivia Dean

STAFF PROFILE

Position

Associate Professor (Research)

Faculty

Faculty of Health

Department

School of Medicine

Campus

HERB

Contact

o.dean@deakin.edu.au
+61342153300

Publications

Filter by

2022

Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder

R Zazula, S Dodd, O Dean, M Berk, C Bortolasci, W Verri, H Vargas, S Nunes

(2022), Vol. 23, pp. 67-77, World Journal of Biological Psychiatry, England, C1

journal article

Cognitive Profile and Relationship with Quality of Life and Psychosocial Functioning in Mood Disorders

R Zazula, M Mohebbi, S Dodd, O Dean, M Berk, H Vargas, S Nunes

(2022), Vol. 37, pp. 376-389, Archives of Clinical Neuropsychology, United States, C1

journal article

The influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: A systematic review and meta-analysis

A Wrobel, A Jayasinghe, S Russell, W Marx, L Alameda, O Dean, S Cotton, M Berk, A Turner

(2022), Vol. 296, pp. 350-362, Journal of Affective Disorders, Amsterdam, The Netherlands, C1

journal article

The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes

B Mitchell, A Campos, D Whiteman, C Olsen, S Gordon, A Walker, O Dean, M Berk, I Hickie, S Medland, N Wray, N Martin, E Byrne

(2022), Vol. 92, pp. 227-235, Biological Psychiatry, United States, C1

journal article

Effect of Glucocorticoid and 11 beta-Hydroxysteroid-Dehydrogenase Type 1 (11 beta-HSD1) in Neurological and Psychiatric Disorders

Seetal Dodd, David Skvarc, Olivia Dean, Anna Anderson, Mark Kotowicz, Michael Berk

(2022), Vol. 25, pp. 387-398, International Journal of Neuropsychopharmacology, Oxford, Eng., C1

journal article

Childhood trauma and treatment outcomes during mood‐stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder

A Wrobel, O Köhler‐Forsberg, L Sylvia, S Russell, O Dean, S Cotton, M Thase, J Calabrese, T Deckersbach, M Tohen, C Bowden, M McInnis, J Kocsis, E Friedman, T Ketter, R Shelton, M Ostacher, D Iosifescu, M Berk, A Turner, A Nierenberg

(2022), Vol. 145, pp. 615-627, Acta Psychiatrica Scandinavica, London, England, C1

journal article

Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder

Anna Wrobel, Samantha Russell, Anuradhi Jayasinghe, Mojtaba Lotfaliany, Alyna Turner, Olivia Dean, Sue Cotton, Claudia Diaz‐Byrd, Anastasia Yocum, Elizabeth Duval, Tobin Ehrlich, David Marshall, Michael Berk, Melvin McInnis

(2022), Vol. 145, pp. 591-603, Acta Psychiatrica Scandinavica, London, Eng., C1

journal article

N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial

J Sarris, G Byrne, D Castle, C Bousman, G Oliver, L Cribb, S Blair-West, V Brakoulias, D Camfield, C Ee, S Chamoli, M Boschen, O Dean, N Dowling, R Menon, J Murphy, N Metri, T Nguyen, A Wong, R Jordan, D Karamacoska, S Rossell, M Berk, C Ng

(2022), Vol. 117, pp. 1-9, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Amsterdam, The Netherlands, C1

journal article

Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce

J Sarris, A Ravindran, L Yatham, W Marx, J Rucklidge, R McIntyre, S Akhondzadeh, F Benedetti, C Caneo, H Cramer, L Cribb, M de Manincor, O Dean, A Deslandes, M Freeman, B Gangadhar, B Harvey, S Kasper, J Lake, A Lopresti, L Lu, N Metri, D Mischoulon, C Ng, D Nishi, R Rahimi, S Seedat, J Sinclair, K Su, Z Zhang, M Berk

(2022), pp. 1-32, World Journal of Biological Psychiatry, London, Eng., C1

journal article

Common effects of bipolar disorder medications on expression quantitative trait loci genes

T Truong, C Bortolasci, S Kidnapillai, B Spolding, B Panizzutti, Z Liu, B Watmuff, J Kim, O Dean, M Richardson, M Berk, K Walder

(2022), Vol. 150, pp. 105-112, Journal of Psychiatric Research, Amsterdam, The Netherlands, C1

journal article

Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder

Trang Truong, Chiara Bortolasci, Briana Spolding, Bruna Panizzutti, Zoe Liu, Srisaiyini Kidnapillai, Mark Richardson, Laura Gray, Craig Smith, Olivia Dean, Jee Kim, Michael Berk, Ken Walder

(2022), Vol. 13, pp. 1-12, Frontiers in Pharmacology, Lausanne, Switzerland, C1

journal article

Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression

Samantha Russell, Anna Wrobel, Olivia Dean, Michael Berk, Seetal Dodd, Chee Ng, Gin Malhi, Susan Cotton, Jerome Sarris, Alyna Turner

(2022), Vol. 20, pp. 300-310, Clinical psychopharmacology and neuroscience, Seoul, Korea (South), C1

journal article

N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms

Erica Neill, Susan Rossell, Caitlin Yolland, Denny Meyer, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia Dean, Paul Francis, Dennis Liu, Andrea Phillipou, Jerome Sarris, David Castle

(2022), pp. 1-10, Schizophrenia Bulletin, Oxford, Eng., C1

journal article
2021

Modeling psychological function in patients with schizophrenia with the PANSS: An international multi-center study

K Fountoulakis, E Dragioti, A Theofilidis, T Wiklund, X Atmatzidis, I Nimatoudis, E Thys, M Wampers, L Hranov, T Hristova, D Aptalidis, R Milev, F Iftene, F Spaniel, P Knytl, P Furstova, T From, H Karlsson, M Walta, R Salokangas, J Azorin, J Bouniard, J Montant, G Juckel, I Haussleiter, A Douzenis, I Michopoulos, P Ferentinos, N Smyrnis, L Mantonakis, Z Nemes, X Gonda, D Vajda, A Juhasz, A Shrivastava, J Waddington, M Pompili, A Comparelli, V Corigliano, E Rancans, A Navickas, J Hilbig, L Bukelskis, L Stevovic, S Vodopic, O Esan, O Oladele, C Osunbote, J Rybakowski, P Wojciak, K Domowicz, M Figueira, L Linhares, J Crawford, A Panfil, D Smirnova, O Izmailova, D Lecic-Tosevski, H Temmingh, F Howells, J Bobes, M Garcia-Portilla, L García-Alvarez, G Erzin, H Karadaǧ, A De Sousa, A Bendre, C Hoschl, C Bredicean, I Papava, O Vukovic, B Pejuskovic, V Russell, L Athanasiadis, A Konsta, D Stein, M Berk, O Dean, R Tandon, S Kasper, M De Hert

(2021), Vol. 26, pp. 290-298, CNS Spectrums, United States, C1

journal article

A novel way to quantify schizophrenia symptoms in clinical trials

O Medvedev, M Berk, O Dean, E Brown, M Sandham, J Dipnall, R McNamara, A Sumich, C Krägeloh, A Narayanan, R Siegert

(2021), Vol. 51, European Journal of Clinical Investigation, England, C1

journal article

A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder

M Ashton, B Kavanagh, W Marx, M Berk, J Sarris, C Ng, M Hopwood, L Williams, O Dean

(2021), Vol. 66, pp. 262-273, Canadian Journal of Psychiatry, United States, C1

journal article

Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial

R McKETIN, B Quinn, P Higgs, M Berk, O Dean, A Turner, P Kelly, D Lubman, G Carter, A Baker, V Manning, T Thomas, R Bathish, D Raftery, L Saunders, A Wrobel, A Meehan, B Sinclair, D Reid, S Arunogiri, H Hill, F Cordaro, P Dietze

(2021), Vol. 40, pp. 1249-1255, Drug and Alcohol Review, Australia, C1

journal article

Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials

R Zazula, M Husain, M Mohebbi, A Walker, I Chaudhry, A Khoso, M Ashton, B Agustini, N Husain, J Deakin, A Young, M Berk, B Kanchanatawan, C Ng, M Maes, L Berk, A Singh, G Malhi, O Dean

(2021), Vol. 55, pp. 784-798, Australian and New Zealand Journal of Psychiatry, England, C1

journal article

Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders

B Kavanagh, M Ashton, S Cowdery, O Dean, A Turner, M Berk, S Gwini, S Brennan-Olsen, H Koivumaa-Honkanen, A Chanen, L Williams

(2021), Vol. 279, pp. 711-721, Journal of affective disorders, Amsterdam, The Netherlands, C1

journal article

Relationships Between Different Dimensions of Social Support and Suicidal Ideation in Young People with Major Depressive Disorder

C Moller, S Cotton, P Badcock, S Hetrick, M Berk, O Dean, A Chanen, C Davey

(2021), Vol. 281, pp. 714-720, Journal of Affective Disorders, Netherlands, C1

journal article

Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe d'appoint Garcinia mangostana Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placebo

A Turner, A Baker, O Dean, A Walker, S Dodd, S Cotton, J Scott, B Kavanagh, M Ashton, E Brown, J McGrath, M Berk

(2021), Vol. 66, pp. 354-366, Canadian Journal of Psychiatry, United States, C1

journal article

Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: a systematic review and meta analysis

T Purton, L Staskova, M Lane, S Dawson, M West, J Firth, G Clarke, J Cryan, M Berk, A O'Neil, O Dean, A Hadi, C Honan, W Marx

(2021), Vol. 123, pp. 1-13, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal article

Age as a predictor of quit attempts and quit success in smoking cessation: findings from the International Tobacco Control Four-Country survey (2002-14)

L Arancini, R Borland, M Le Grande, M Mohebbi, S Dodd, O Dean, M Berk, A McNeill, G Fong, K Cummings

(2021), Vol. 116, pp. 2509-2520, Addiction, England, C1

journal article

Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people

K Witt, T Madsen, M Berk, O Dean, A Chanen, P McGorry, S Cotton, C Davey, S Hetrick

(2021), Vol. 55, pp. 506-516, Australian and New Zealand Journal of Psychiatry, England, C1

journal article

The Added Burden of Personality Disorder on Subsidized Australian Health Service Utilization Among Women With Mental State Disorder

Bianca Kavanagh, Stella Gwini, Julie Pasco, Amanda Stuart, Shae Quirk, James Gaston, Kara Holloway-Kew, Alyna Turner, Michael Berk, Olivia Dean, Andrew Chanen, Heli Koivumaa-Honkanen, Paul Moran, Rohan Borschmann, Lana Williams

(2021), Vol. 2, pp. 1-8, Frontiers in Global Women's Health, Lausanne, Switzerland, C1

journal article

Influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: protocol for a systematic review and meta-analysis

A Wrobel, S Russell, O Dean, S Cotton, M Berk, A Turner

(2021), Vol. 11, pp. 1-8, BMJ open, London, Eng., C1

journal article

Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use

D Raftery, P Kelly, F Deane, G Carter, O Dean, D Lubman, A Turner, R McKetin

(2021), Vol. 130, Journal of Substance Abuse Treatment, United States, C1

journal article

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

W Marx, D Skvarc, M Mohebbi, A Walker, A Meehan, A Turner, A Baker, S Dodd, S Cotton, J Scott, B Kavanagh, M Ashton, E Brown, J McGrath, M Berk, O Dean

(2021), Vol. 12, Frontiers in Psychiatry, Switzerland, C1

journal article

Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study

J Sarris, G Byrne, G Oliver, L Cribb, S Blair-West, D Castle, O Dean, D Camfield, V Brakoulias, C Bousman, N Dowling, C Ee, J Murphy, R Menon, M Berk, S Chamoli, M Boschen, C Ng

(2021), CNS Spectrums, United States, C1

journal article

Transcriptional modulation of the hippo signaling pathway by drugs used to treat bipolar disorder and schizophrenia

B Panizzutti, C Bortolasci, B Spolding, S Kidnapillai, T Connor, M Richardson, T Truong, Z Liu, G Morris, L Gray, J Kim, O Dean, M Berk, K Walder

(2021), Vol. 22, International Journal of Molecular Sciences, Switzerland, C1

journal article

Statins: Neurobiological underpinnings and mechanisms in mood disorders

A Walker, Y Kim, I Borissiouk, R Rehder, S Dodd, G Morris, A Nierenberg, M Maes, B Fernandes, O Dean, L Williams, H Eyre, S Kim, S Zoungas, A Carvalho, M Berk

(2021), Vol. 128, pp. 693-708, Neuroscience and Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal article

N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial

R McKetin, O Dean, A Turner, P Kelly, B Quinn, D Lubman, P Dietze, G Carter, P Higgs, B Sinclair, D Reid, A Baker, V Manning, N Pas, T Thomas, R Bathish, D Raftery, A Wrobel, L Saunders, S Arunogiri, F Cordaro, H Hill, S Hall, P Clare, M Mohebbi, M Berk

(2021), Vol. 38, eClinicalMedicine, England, C1

journal article

Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial

C Bortolasci, A Turner, M Mohebbi, Z Liu, M Ashton, L Gray, W Marx, A Walker, G Kowalski, F Jacka, M Berk, O Dean, K Walder

(2021), Vol. 142, pp. 376-383, Journal of Psychiatric Research, England, C1

journal article

Gender, age at onset and duration of being ill as predictors for the long-term course and outcome of Schizophrenia: An international multi-center study

K Fountoulakis, E Dragioti, A Theofilidis, T Wiklund, X Atmatzidis, I Nimatoudis, E Thys, M Wampers, L Hranov, T Hristova, D Aptalidis, R Milev, F Iftene, F Spaniel, P Knytl, P Furstova, T From, H Karlsson, M Walta, R Salokangas, J Azorin, J Bouniard, J Montant, G Juckel, I Haussleiter, A Douzenis, I Michopoulos, P Ferentinos, N Smyrnis, L Mantonakis, Z Nemes, X Gonda, D Vajda, A Juhasz, A Shrivastava, J Waddington, M Pompili, A Comparelli, V Corigliano, E Rancans, A Navickas, J Hilbig, L Bukelskis, L Stevovic, S Vodopic, O Esan, O Oladele, C Osunbote, J Rybakowski, P Wojciak, K Domowicz, M Figueira, L Linhares, J Crawford, A Panfil, D Smirnova, O Izmailova, D Lecic-Tosevski, H Temmingh, F Howells, J Bobes, M Garcia-Portilla, L García-Alvarez, G Erzin, H Karadağ, A de Sousa, A Bendre, C Hoschl, C Bredicean, I Papava, O Vukovic, B Pejuskovic, V Russell, L Athanasiadis, A Konsta, D Stein, M Berk, O Dean, R Tandon, S Kasper, M de Hert

(2021), CNS Spectrums, United States, C1

journal article

Biological mechanism(S) underpinning the association between antipsychotic drugs and weight gain

B Panizzutti, C Bortolasci, B Spolding, S Kidnapillai, T Connor, M Richardson, T Truong, Z Liu, L Gray, J Kim, O Dean, M Berk, K Walder

(2021), Vol. 10, Journal of Clinical Medicine, Switzerland, C1

journal article

A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking

L Arancini, M Mohebbi, M Berk, O Dean, C Bortolasci, B Spolding, R Zazula, S Dodd

(2021), Vol. 53, pp. 120-126, European Neuropsychopharmacology, Amsterdam, The Netherlands, C1

journal article

Dietary quality and nutrient intake in adults with obsessive-compulsive disorder

T Nguyen, L Cribb, C Ng, G Byrne, D Castle, V Brakoulias, S Blair-West, G Oliver, C Ee, O Dean, D Camfield, C Bousman, N Dowling, R Roy, M Berk, J Sarris

(2021), Vol. 7, BJPsych Open, C1

journal article

Exploring interleukin-6, lipopolysaccharide binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression

K Hasebe, M Mohebbi, L Gray, A Walker, C Bortolasci, A Turner, M Berk, K Walder, M Maes, B Kanchanatawan, M Ashton, L Berk, C Ng, G Malhi, A Singh, O Dean

(2021), Vol. 34, Acta Neuropsychiatrica, England, C1

journal article
2020

Improvement of cognitive function in schizophrenia with N-acetylcysteine: a theoretical review

C Yolland, A Phillipou, D Castle, E Neill, M Hughes, C Galletly, Z Smith, P Francis, O Dean, J Sarris, D Siskind, A Harris, S Rossell

(2020), Vol. 23, pp. 139-148, Nutritional neuroscience, Abingdon, Eng., C1

journal article

The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder

S Kidnapillai, C Bortolasci, M Udawela, B Panizzutti, B Spolding, T Connor, A Sanigorski, O Dean, T Crowley, S Jamain, L Gray, E Scarr, M Leboyer, B Dean, M Berk, K Walder

(2020), Vol. 21, pp. 775-783, World Journal of Biological Psychiatry, England, C1

journal article

The effect of blueberry interventions on cognitive performance and mood: A systematic review of randomized controlled trials

N Travica, N D'Cunha, N Naumovski, K Kent, D Mellor, J Firth, E Georgousopoulou, O Dean, A Loughman, F Jacka, W Marx

(2020), Vol. 85, pp. 96-105, Brain, Behavior, and Immunity, Netherlands, C1

journal article

Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial

Bianca Kavanagh, Lana Williams, Michael Berk, Alyna Turner, Henry Jackson, Mohammadreza Mohebbi, Buranee Kanchanatawan, Melanie Ashton, Chee Ng, Michael Maes, Lesley Berk, Gin Malhi, Nathan Dowling, Ajeet Singh, Olivia Dean

(2020), Vol. 42, pp. 14-21, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

journal article

Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: a sub-study of a randomised placebo-controlled trial

M Ashton, O Dean, W Marx, M Mohebbi, M Berk, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, M Hopwood, K Faye-Chauhan, Y Kim, S Dash, F Jacka, N Shivappa, J Hebert, A Turner

(2020), Vol. 54, pp. 159-172, Australian and New Zealand journal of psychiatry, London, Eng., C1

journal article

The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review

W Marx, M Hockey, A McGuinness, M Lane, J Christodoulou, I van der Mei, M Berk, O Dean, B Taylor, S Broadley, J Lechner-Scott, F Jacka, R Lucas, A Ponsonby

(2020), Vol. 37, Multiple Sclerosis and Related Disorders, Netherlands, C1

journal article

Physical activity as a predictor of clinical trial outcomes in bipolar depression: a subanalysis of a mitochondrial-enhancing nutraceutical randomized controlled trial

M Ashton, M Mohebbi, A Turner, W Marx, M Berk, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, M Hopwood, B Stubbs, O Dean

(2020), Vol. 65, pp. 306-318, Canadian journal of psychiatry, London, Eng., C1

journal article

Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia

C Yolland, D Hanratty, E Neill, S Rossell, M Berk, O Dean, D Castle, E Tan, A Phillipou, A Harris, A Barreiros, A Hansen, D Siskind

(2020), Vol. 54, pp. 453-466, Australian and New Zealand journal of psychiatry, London, Eng., C1

journal article

Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): A randomised clinical trial of rosuvastatin and aspirin

M Berk, M Mohebbi, O Dean, S Cotton, A Chanen, S Dodd, A Ratheesh, G Amminger, M Phelan, A Weller, A MacKinnon, F Giorlando, S Baird, L Incerti, R Brodie, N Ferguson, S Rice, M Schäfer, E Mullen, S Hetrick, M Kerr, S Harrigan, A Quinn, C Mazza, P McGorry, C Davey

(2020), Vol. 18, BMC Medicine, England, C1

journal article

Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis

C Bortolasci, W Marx, A Walker, K Hasebe, B Kavanagh, M Morris, M Mohebbi, A Turner, L Gray, L Berk, K Walder, M Berk, O Dean

(2020), Vol. 10, pp. e035080-, BMJ open, England, C1

journal article

Studies on Haloperidol and Adjunctive α-Mangostin or Raw Garcinia mangostana Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats

J Lotter, M Möller, O Dean, M Berk, B Harvey

(2020), Vol. 11, Frontiers in Psychiatry, Switzerland, C1

journal article

Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder

C Bortolasci, C Voigt, A Turner, M Mohebbi, L Gray, S Dodd, K Walder, M Berk, S Cotton, G Malhi, C Ng, N Dowling, J Sarris, O Dean

(2020), Vol. 32, pp. 313-320, Acta Neuropsychiatrica, England, C1

journal article

Personality disorder increases risk of low quality of life among women with mental state disorders

B Kavanagh, A Stuart, M Berk, A Turner, O Dean, J Pasco, H Jackson, H Koivumaa-Honkanen, A Chanen, L Williams

(2020), Vol. 102, Comprehensive Psychiatry, United States, C1

journal article

Insight in substance use disorder: A systematic review of the literature

D Raftery, P Kelly, F Deane, A Baker, I Ingram, M Goh, D Lubman, G Carter, A Turner, O Dean, B Sinclair, R McKetin

(2020), Vol. 111, Addictive Behaviors, England, C1

journal article

Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials

Wolfgang Marx, Andrew Scholey, Joseph Firth, Nathan D’Cunha, Melissa Lane, Meghan Hockey, Melanie Ashton, John Cryan, A O'Neil, Nenad Naumovski, Michael Berk, Olivia Dean, Felice Jacka

(2020), Vol. 118, pp. 472-484, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal article

Transcriptional effects of psychoactive drugs on genes involved in neurogenesis

C Bortolasci, B Spolding, S Kidnapillai, T Connor, T Truong, Z Liu, B Panizzutti, M Richardson, L Gray, M Berk, O Dean, K Walder

(2020), Vol. 21, pp. 1-19, International Journal of Molecular Sciences, Switzerland, C1

journal article

Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis: A Randomized Clinical Trial

J Scott, A Baker, C Lim, S Foley, F Dark, A Gordon, D Ward, D Richardson, G Bruxner, K Beckmann, S Hatherill, S Stathis, K Dixon, A Ryan, B McWhinney, J Ungerer, M Berk, O Dean, S Saha, J McGrath

(2020), Vol. 3, pp. e2024335-, JAMA network open, United States, C1

journal article
2019

A randomized controlled trial of MoodSwings 2.0: An internet-based self-management program for bipolar disorder

E Gliddon, V Cosgrove, L Berk, S Lauder, M Mohebbi, D Grimm, S Dodd, C Coulson, K Raju, T Suppes, M Berk

(2019), Vol. 21, pp. 28-39, Bipolar Disorders, London, Eng., C1

journal article

Does N-acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of N-acetylcysteine

O Dean, K Gray, S Dodd, K Villagonzalo, E Brown, B Tonge, M Berk, L Byrne

(2019), Vol. 44, pp. 474-480, Journal of Intellectual and Developmental Disability, C1

journal article

Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice Jacka, Susan Cotton, Jon-Paul Khoo, Mary Chatterton, Bianca Kavanagh, Sarah Nadjidai, Samantha Lo Monaco, Brian Harvey, Jerome Sarris, Gin Malhi, Nathan Dowling, Olivia Dean

(2019), Vol. 41, pp. 245-253, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

journal article

The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study

P Ellegaard, R Licht, R Nielsen, O Dean, M Berk, H Poulsen, M Mohebbi, C Nielsen

(2019), Vol. 245, pp. 1043-1051, Journal of Affective Disorders, Netherlands, C1

journal article

A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: Mitochondrial agents, N-acetylcysteine, and placebo

M Berk, A Turner, G Malhi, C Ng, S Cotton, S Dodd, Y Samuni, M Tanious, C McAulay, N Dowling, J Sarris, L Owen, A Waterdrinker, D Smith, O Dean

(2019), Vol. 17, BMC Medicine, England, C1

journal article

The therapeutic potential of mangosteen pericarp as an adjunctive therapy for bipolar disorder and schizophrenia

M Ashton, O Dean, A Walker, C Bortolasci, C Ng, M Hopwood, B Harvey, M Möller, J McGrath, W Marx, A Turner, S Dodd, J Scott, J Khoo, K Walder, J Sarris, M Berk

(2019), Vol. 10, Frontiers in Psychiatry, Switzerland, C1

journal article

Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Alyna Turner, John McGrath, Olivia Dean, Seetal Dodd, Andrea Baker, Susan Cotton, James Scott, Bianca Kavanagh, Melanie Ashton, Adam Walker, Ellie Brown, Michael Berk

(2019), Vol. 17, pp. 297-307, Clinical psychopharmacology and neuroscience, Seoul, South Korea, C1

journal article

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: Protocol for a systematic review

M Ashton, M Berk, C Ng, M Hopwood, B Kavanagh, L Williams, J Sarris, O Dean

(2019), Vol. 9, BMJ Open, England, C1

journal article

Protocol update and statistical analysis plan for CADENCE-BZ: A randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis

C Lim, A Baker, S Saha, S Foley, A Gordon, D Ward, B Burgher, F Dark, M Beckmann, S Stathis, G Bruxner, A Ryan, D Richardson, S Hatherill, M Berk, O Dean, J McGrath, J Chapman, S Patterson, S Singh, B Mowry, L Tracy, M Duhig, A Machin, E Troman, S Suetani, T Dinala, L Burton, P Cosgrove, C Gamble, J Scott

(2019), Vol. 20, Trials, England, C1

journal article

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis

Wolfgang Marx, Melissa Lane, Tetyana Rocks, Anu Ruusunen, Amy Loughman, Adrian Lopresti, Skye Marshall, Michael Berk, Felice Jacka, Olivia Dean

(2019), Vol. 77, pp. 557-571, Nutrition reviews, Oxford, Eng., C1

journal article

A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence

R McKetin, O Dean, A Turner, P Kelly, B Quinn, D Lubman, P Dietze, G Carter, P Higgs, A Baker, B Sinclair, D Reid, V Manning, N Te Pas, W Liang, T Thomas, R Bathish, M Kent, D Raftery, S Arunogiri, F Cordaro, H Hill, M Berk

(2019), Vol. 20, Trials, England, C1

journal article

Measuring cognitive insight in people with problematic substance use: an exploration of the factor validity of the Beck Cognitive Insight Scale

D Raftery, P Kelly, F Deane, R Mcketin, A Baker, A Turner, O Dean

(2019), Vol. 38, pp. 622-629, Drug and alcohol review, Chichester, Eng., C1

journal article

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial

C Davey, A Chanen, S Hetrick, S Cotton, A Ratheesh, G Amminger, J Koutsogiannis, M Phelan, E Mullen, B Harrison, S Rice, A Parker, O Dean, A Weller, M Kerr, A Quinn, L Catania, N Kazantzis, P McGorry, M Berk

(2019), Vol. 6, pp. 735-744, The Lancet Psychiatry, England, C1

journal article

Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline

K Hasebe, L Rivera, C Smith, T Allnutt, T Crowley, T Nelson, O Dean, S McGee, K Walder, L Gray

(2019), Vol. 82, pp. 309-318, Brain, Behavior, and Immunity, Netherlands, C1

journal article

N-acetylcysteine for cessation of tobacco smoking: Rationale and study protocol for a randomised controlled trial

L Arancini, C Bortolasci, S Dodd, O Dean, M Berk

(2019), Vol. 20, Trials, England, C1

journal article

Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis - a possible therapeutic mechanism

S Kidnapillai, C Bortolasci, B Panizzutti, B Spolding, T Connor, K Bonifacio, A Sanigorski, O Dean, T Crowley, S Jamain, L Gray, M Leboyer, M Berk, K Walder

(2019), Vol. 20, pp. 766-777, World Journal of Biological Psychiatry, London, Eng., C1

journal article

Staging of Schizophrenia with the Use of PANSS: An International Multi-Center Study

K Fountoulakis, E Dragioti, A Theofilidis, T Wikilund, X Atmatzidis, I Nimatoudis, E Thys, M Wampers, L Hranov, T Hristova, D Aptalidis, R Milev, F Iftene, F Spaniel, P Knytl, P Furstova, T From, H Karlsson, M Walta, R Salokangas, J Azorin, J Bouniard, J Montant, G Juckel, I Haussleiter, A Douzenis, I Michopoulos, P Ferentinos, N Smyrnis, L Mantonakis, Z Nemes, X Gonda, D Vajda, A Juhasz, A Shrivastava, J Waddington, M Pompili, A Comparelli, V Corigliano, E Rancans, A Navickas, J Hilbig, L Bukelskis, L Injac Stevovic, S Vodopic, O Esan, O Oladele, C Osunbote, J Rybakowski, P Wojciak, K Domowicz, M Figueira, L Linhares, J Crawford, A Panfil, D Smirnova, O Izmailova, D Lecic-Tosevski, H Temmingh, F Howells, J Bobes, M Garcia-Portilla, L García-Alvarez, G Erzin, H Karadaǧ, A De Sousa, A Bendre, C Hoschl, C Bredicean, I Papava, O Vukovic, B Pejuskovic, V Russell, L Athanasiadis, A Konsta, D Stein, M Berk, O Dean, R Tandon, S Kasper, M De Hert

(2019), Vol. 22, pp. 681-697, International Journal of Neuropsychopharmacology, Oxford, Eng., C1

journal article

ENACT: A protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

S Cotton, M Berk, A Watson, S Wood, K Allott, C Bartholomeusz, C Bortolasci, K Walder, B O'Donoghue, O Dean, A Chanen, G Amminger, P McGorry, A Burnside, J Uren, A Ratheesh, S Dodd

(2019), Vol. 20, Trials, England, C1

journal article
2018

Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin

A Quinn, O Dean, C Davey, M Kerr, S Harrigan, S Cotton, A Chanen, S Dodd, A Ratheesh, G Amminger, M Phelan, A Williams, A Mackinnon, F Giorlando, S Baird, S Rice, M O'Shea, M Schäfer, E Mullen, S Hetrick, P McGorry, M Berk

(2018), Vol. 12, pp. 45-54, Early Intervention in Psychiatry, Australia, C1

journal article

Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat

I Oberholzer, M Möller, B Holland, O Dean, M Berk, B Harvey

(2018), Vol. 33, pp. 467-480, Metabolic Brain Disease, United States, C1

journal article

Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapies

D Skvarc, M Berk, L Byrne, O Dean, S Dodd, M Lewis, A Marriott, E Moore, G Morris, R Page, L Gray

(2018), Vol. 84, pp. 116-133, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal article

An update on adjunctive treatment options for bipolar disorder

O Dean, E Gliddon, T Van Rheenen, F Giorlando, S Davidson, M Kaur, T Ngo, L Williams

(2018), Vol. 20, pp. 87-96, Bipolar Disorders, Denmark, C1

journal article

Mechanisms underpinning the polypharmacy effects of medications in psychiatry

C Bortolasci, B Spolding, E Callaly, S Martin, B Panizzutti, S Kidnapillai, T Connor, K Hasebe, M Mohebbi, O Dean, S McGee, S Dodd, L Gray, M Berk, K Walder

(2018), Vol. 21, pp. 582-591, International Journal of Neuropsychopharmacology, England, C1

journal article

Mitochondrial agents for bipolar disorder

C Pereira, V Chavarria, J Vian, M Ashton, M Berk, W Marx, O Dean

(2018), Vol. 21, pp. 550-569, International Journal of Neuropsychopharmacology, England, C1

journal article

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)

P Ellegaard, R Licht, H Poulsen, R Nielsen, M Berk, O Dean, M Mohebbi, C Nielsen

(2018), Vol. 6, International Journal of Bipolar Disorders, Germany, C1

journal article

Patient centric measures for a patient centric era: Agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder

M Mohebbi, S Dodd, O Dean, M Berk

(2018), Vol. 53, pp. 17-22, European Psychiatry, England, C1

journal article

Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression

B Panizzutti, C Bortolasci, K Hasebe, S Kidnapillai, L Gray, K Walder, M Berk, M Mohebbi, S Dodd, C Gama, P Magalhães, S Cotton, F Kapczinski, A Bush, G Malhi, O Dean

(2018), Vol. 30, pp. 334-341, Acta Neuropsychiatrica, England, C1

journal article
2017

A potential role for N-acetylcysteine in the management of methamphetamine dependence

R McKetin, O Dean, A Baker, G Carter, A Turner, P Kelly, M Berk

(2017), Vol. 36, pp. 153-159, Drug and Alcohol Review, Australia, C1

journal article

A randomised, double blind, placebo-controlled trial of a fixed dose of N -acetyl cysteine in children with autistic disorder

O Dean, K Gray, K Villagonzalo, S Dodd, M Mohebbi, T Vick, B Tonge, M Berk

(2017), Vol. 51, pp. 241-249, Australian and New Zealand Journal of Psychiatry, England, C1

journal article

Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology

J Data-Franco, A Singh, D Popovic, M Ashton, M Berk, E Vieta, M Figueira, O Dean

(2017), Vol. 72, pp. 73-86, Progress in neuro-psychopharmacology & biological psychiatry, Amsterdam, The Netherlands, C1

journal article

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

M Rapado-Castro, S Dodd, A Bush, G Malhi, D Skvarc, Z On, M Berk, O Dean

(2017), Vol. 47, pp. 866-876, Psychological Medicine, England, C1

journal article

A model of the mitochondrial basis of bipolar disorder

G Morris, K Walder, S McGee, O Dean, S Tye, M Maes, M Berk

(2017), Vol. 74, pp. 1-20, Neuroscience and Biobehavioral Reviews, United States, C1

journal article

A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial)

F Jacka, A O'Neil, R Opie, C Itsiopoulos, S Cotton, M Mohebbi, D Castle, S Dash, C Mihalopoulos, M Chatterton, L Brazionis, O Dean, A Hodge, M Berk

(2017), Vol. 15, BMC Medicine, England, C1

journal article

A review of the theoretical and biological understanding of the nocebo and placebo phenomena

S Dodd, O Dean, J Vian, M Berk

(2017), Vol. 39, pp. 469-476, Clinical therapeutics, Amsterdam, The Netherlands, C1

journal article

Adjunctive N-acetylcysteine in depression: Exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor

K Hasebe, L Gray, C Bortolasci, B Panizzutti, M Mohebbi, S Kidnapillai, B Spolding, K Walder, M Berk, G Malhi, S Dodd, O Dean

(2017), Vol. 29, pp. 337-346, Acta Neuropsychiatrica, England, C1

journal article

The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: Study protocol for a randomized controlled trial

A Ryan, A Baker, F Dark, S Foley, A Gordon, S Hatherill, S Stathis, S Saha, G Bruxner, M Beckman, D Richardson, M Berk, O Dean, J McGrath, C Group, J Scott

(2017), Vol. 18, Trials, England, C1

journal article

the effect of n-acetylcysteine (nac) on human cognition - a systematic review

D Skvarc, O Dean, L Byrne, L Gray, S Lane, M Lewis, B Fernandes, M Berk, A Marriott

(2017), Vol. 78, pp. 44-56, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal article

Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial

O Dean, B Kanchanatawan, M Ashton, M Mohebbi, C Ng, M Maes, L Berk, A Sughondhabirom, S Tangwongchai, A Singh, H McKenzie, D Smith, G Malhi, N Dowling, M Berk

(2017), Vol. 51, pp. 829-840, Australian and New Zealand Journal of Psychiatry, England, C1

journal article

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: a 16-week open-label pilot study

R Menon, L Cribb, J Murphy, M Ashton, G Oliver, N Dowling, A Turner, O Dean, M Berk, C Ng, J Sarris

(2017), Vol. 4, pp. 109-114, Advances in integrative medicine, Amsterdam, The Netherlands, C1

journal article
2016

C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: Meta-analysis and implications

B Fernandes, J Steiner, H Bernstein, S Dodd, J Pasco, O Dean, P Nardin, C Gonçalves, M Berk

(2016), Vol. 21, pp. 554-564, Molecular Psychiatry, England, C1

journal article

A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis

J Davis, H Eyre, F Jacka, S Dodd, O Dean, S McEwen, M Debnath, J McGrath, M Maes, P Amminger, P McGorry, C Pantelis, M Berk

(2016), Vol. 65, pp. 185-194, Neuroscience and Biobehavioral Reviews, United States, C1

journal article

Antioxidant treatments for schizophrenia

P Magalhães, O Dean, A Andreazza, M Berk, F Kapczinski

(2016), Vol. 2016, Cochrane Database of Systematic Reviews, England, C1

journal article

N-acetylcysteine in depressive symptoms and functionality: A systematic review and meta-analysis

B Fernandes, O Dean, S Dodd, G Malhi, M Berk

(2016), Vol. 77, pp. e457-e466, Journal of Clinical Psychiatry, United States, C1

journal article

The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: Study protocol for a randomised controlled trial

D Skvarc, O Dean, L Byrne, L Gray, K Ives, S Lane, M Lewis, C Osborne, R Page, D Stupart, A Turner, M Berk, A Marriott

(2016), Vol. 17, Trials, England, C1

journal article

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: A double blind randomised placebo controlled trial targeting negative symptoms

S Rossell, P Francis, C Galletly, A Harris, D Siskind, M Berk, K Bozaoglu, F Dark, O Dean, D Liu, D Meyer, E Neill, A Phillipou, J Sarris, D Castle

(2016), Vol. 16, BMC Psychiatry, England, C1

journal article

Participant characteristics as modifiers of response to N-Acetyl cysteine (NAC) in obsessive-compulsive disorder

J Sarris, G Oliver, D Camfield, O Dean

(2016), Vol. 4, pp. 1104-1111, Clinical psychological science, London, Eng., C1

journal article
2015

The use of mixed methods in drug discovery: integrating qualitative methods into clinical trials

M Berk, R Otmar, O Dean, L Berk, E Michalak

(2015), pp. 59-73, Clinical trial design challenges in mood disorders, Amsterdam, The Netherlands, B1

book chapter

Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

M Rapado-Castro, M Berk, K Venugopal, A Bush, S Dodd, O Dean

(2015), Vol. 57, pp. 69-75, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Amsterdam, The Netherlands, C1

journal article

Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols?

S Nabavi, O Dean, A Turner, A Sureda, M Daglia, S Nabavi

(2015), Vol. 22, pp. 343-351, Current medicinal chemistry, Beijing, China, C1-1

journal article

Tobacco use in bipolar disorder.

D Thomson, M Berk, S Dodd, M Rapado-Castro, S Quirk, P Ellegaard, L Berk, O Dean

(2015), Vol. 13, pp. 1-11, Clinical Psychopharmacology and Neuroscience, Korea (South), C1

journal article

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review

G Oliver, O Dean, D Camfield, S Blair-West, C Ng, M Berk, J Sarris

(2015), Vol. 13, pp. 12-24, Clinical psychopharmacology and neuroscience, Korea (South), C1

journal article

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Deepmala, J Slattery, N Kumar, L Delhey, M Berk, O Dean, C Spielholz, R Frye

(2015), Vol. 55, pp. 294-321, Neuroscience and Biobehavioral Reviews, Amsterdam, The Netherlands, C1

journal article

N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study

J Sarris, G Oliver, D Camfield, O Dean, N Dowling, D Smith, J Murphy, R Menon, M Berk, S Blair-West, C Ng

(2015), Vol. 29, pp. 801-809, CNS Drugs, Berlin, Germany, C1

journal article

Future directions for pharmacotherapies for treatment-resistant bipolar disorder

S Dodd, B Simoes Fernandes, O Dean

(2015), Vol. 13, pp. 656-662, Current neuropharmacology, Bussum, The Netherlands, C1

journal article
2014

Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications

G Anderson, M Berk, O Dean, S Moylan, M Maes

(2014), Vol. 28, CNS Drugs, Aukland, New Zealand, C1

journal article

Post-stroke depression therapy: where are we now?

S Nabavi, A Turner, O Dean, A Sureda, S Nabavi

(2014), Vol. 11, pp. 1-13, Current neurovascular research, Bussum, The Netherlands, C1

journal article

The efficacy of adjunctive N-Acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

M Berk, O Dean, S Cotton, S Jeavons, M Tanious, K Kohlmann, K Hewitt, K Moss, C Allwang, I Schapkaitz, J Robbins, H Cobb, F Ng, S Dodd, A Bush, G Malhi

(2014), Vol. 75, pp. 628-636, Journal of clinical psychiatry, Memphis, Tenn., C1

journal article

Oxidative & nitrosative stress in depression: why so much stress?

S Moylan, M Berk, O Dean, Y Samuni, L Williams, A O'Neil, A Hayley, J Pasco, G Anderson, F Jacka, M Maes

(2014), Vol. 45, pp. 46-62, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

journal article

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

O Dean, A Turner, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, Y Samuni, M Tanious, N Dowling, A Waterdrinker, D Smith, M Berk

(2014), Vol. 0, pp. 1-10, Revista Brasileira de psiquiatria, Sao Paulo, Brazil, C1

journal article

The Glutathione System: a new drug target in neuroimmune disorders

G Morris, G Anderson, O Dean, M Berk, P Galecki, M Martin-Subero, M Maes

(2014), Vol. 50, pp. 1059-1084, Molecular neurobiology, New York, N. Y., C1

journal article

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.

C Davey, A Chanen, S Cotton, S Hetrick, M Kerr, M Berk, O Dean, K Yuen, M Phelan, A Ratheesh, M Schäfer, G Amminger, A Parker, D Piskulic, S Harrigan, A Mackinnon, B Harrison, P McGorry

(2014), Vol. 15, pp. 1-9, Trials, London, Eng., C1

journal article

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial.

O Dean, M Maes, M Ashton, L Berk, B Kanchanatawan, A Sughondhabirom, S Tangwongchai, C Ng, N Dowling, G Malhi, M Berk

(2014), Vol. 12, pp. 180-188, Clinical psychopharmacology and neuroscience, Seoul, Korea, C1

journal article
2013

Putative neuroprotective agents in neuropsychiatric disorders

S Dodd, M Maes, G Anderson, O Dean, S Moylan, M Berk

(2013), Vol. 42, pp. 135-145, Progress in neuro-psychopharmacology and biological psychiatry, United States, C1

journal article

The promise of N-acetylcysteine in neuropsychiatry

M Berk, G Malhi, L Gray, O Dean

(2013), Vol. 34, pp. 167-177, Trends in pharmacological sciences, Oxford, England, C1

journal article

Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo

P Das, M Tanious, K Fritz, S Dodd, O Dean, M Berk, G Malhi

(2013), Vol. 47, pp. 347-354, Australian and New Zealand journal of psychiatry, London, England, C1

journal article

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania

P Vieira da Silva Magalhaes, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2013), Vol. 47, pp. 564-568, Australian and New Zealand journal of psychiatry, London, England, C1

journal article

Aspirin : a review of its neurobiological properties and therapeutic potential for mental illness

M Berk, O Dean, H Drexhage, J McNeil, S Moylan, A O'Neil, C Davey, L Sanna, M Maes

(2013), Vol. 11, pp. 1-17, BMC medicine, London, England, C1

journal article

A randomised, controlled trial of a dietary intervention for adults with major depression (the 'SMILES' trial): study protocol

A O'Neil, M Berk, C Itsiopoulos, D Castle, R Opie, J Pizzinga, L Brazionis, A Hodge, C Mihalopoulos, M Chatterton, O Dean, F Jacka

(2013), Vol. 13, pp. 1-7, BMC psychiatry, London, England, C1

journal article

The chemistry and biological activities of N-acetylcysteine

Y Samuni, S Goldstein, O Dean, M Berk

(2013), Vol. 1830, pp. 4117-4129, Biochim biophys acta, Amsterdam, Netherlands, C1

journal article
2012

Glutamatergic antidepressants

H Kalra, O Dean, S Dodd, M Berk

(2012), pp. 95-107, Antidepressants and Major Depressive Disorder, B1-1

book chapter

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

P Magalhaes, O Dean, A Bush, D Copolov, D Weisinger, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 37, pp. 132-135, Progress in neuro-psychopharmacology and biological psychiatry, Philadelphia, Pa., C1

journal article

Minocycline : therapeutic potential in psychiatry

O Dean, J Data-Franco, F Giorlando, M Berk

(2012), Vol. 26, pp. 391-401, CNS Drugs, Auckland, New Zealand, C1

journal article

Maintenance N-acetyl cysteine treatment for bipolar disorder : a double-blind randomised placebo controlled trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, K Moss, C Allwang, I Schapkaitz, H Cobb, A Bush, S Dodd, G Malhi

(2012), Vol. 10, pp. 1-11, BMC medicine, London, England, C1

journal article

Adjunctive antioxidants for bipolar disorder

P Magalhaes, O Dean, A Andreazza, M Berk, F Kapczinski

(2012), pp. 1-11, The Cochrane collaboration, Oxford, England, C1-1

journal article

Effects of N-acetyl cysteine on cognitive function in bipolar disorder

O Dean, A Bush, D Copolov, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 66, pp. 514-517, Psychiatry and clinical neurosciences, Richmond, Vic., C1

journal article
2011

Qualitative methods in early-phase drug trials : data and methods from a trial of N-acetylcysteine in schizophrenia

M Berk, A Munib, O Dean, G Malhi, K Kohlmann, I Schapkaitz, S Jeavons, F Katz, M Anderson-Hunt, P Conus, B Hanna, R Otmar, F Ng, D Copolov, A Bush

(2011), Vol. 72, pp. 909-913, Journal of clinical psychiatry, [Memphis, Tenn.], C1-1

journal article

N-acetylcysteine in psychiatry - current therapeutic evidence and potential mechanisms of action

O Dean, F Giorlando, M Berk

(2011), Vol. 36, pp. 78-86, Journal of psychiatry and neuroscience, Ottowa, Canada, C1-1

journal article

N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats : relevance to schizophrenia and bipolar disorder

O Dean, M van den Buuse, M Berk, D Copolov, C Mavros, A Bush

(2011), Vol. 499, pp. 149-153, Neuroscience letters, Clare, Ireland, C1-1

journal article

Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease

M Gerlach, G Bartoszyk, P Riederer, O Dean, M van den Buuse

(2011), Vol. 118, pp. 1733-1742, Journal of neural transmission, Amsterdam, The Netherlands, C1-1

journal article

Antioxidant treatments for schizophrenia

P Magalhaes, A Andreazza, M Berk, F Kapczinski, O Dean

(2011), pp. 1-13, Cochrane database of systematic reviews, Oxford, U. K., C1-1

journal article

N-acetyl cysteine add-on treatment for bipolar II disorder : a subgroup analysis of a randomised placebo-controlled trial

P Magalhães, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 129, pp. 317-320, Journal of affective disorders, Amsterdam, The Netherlands, C1-1

journal article

Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder.

P Magalhães, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 23, pp. 87-88, Acta neuropsychiatrica, Oxford, England, C1-1

journal article

Pathways underlying neuroprogression in bipolar disorder : focus on inflammation, oxidative stress and neurotrophic factors

M Berk, F Kapczinski, A Andreazza, O Dean, F Giorlando, M Maes, M Yücel, C Gama, S Dodd, B Dean, P Magalhães, P Amminger, P McGorry, G Malhi

(2011), Vol. 35, pp. 804-817, Neuroscience & biobehavioral reviews, Oxford, England, C1-1

journal article

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression : an open label trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, C Allwang, H Cobb, A Bush, I Schapkaitz, S Dodd, G Malhi

(2011), Vol. 135, pp. 389-394, Journal of affective disorders, Amsterdam, Netherlands, C1

journal article

Who's left? Symptoms of schizophrenia that predict clinical trial dropout

J Thompson, M Berk, O Dean, K Kohlmann, S Jeavons, A Bush, D Copolov

(2011), Vol. 26, pp. 609-613, Human psychopharmacology, West Sussex, England, C1-1

journal article

N-acetylcysteine for major depressive episodes in bipolar disorder

P Magalhães, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 33, pp. 374-378, Revista Brasileira de Psiquiatria, Sao Paulo, Brazil, C1

journal article
2010

Effects of n-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats

K Choy, O Dean, M Berk, A Bush, M van den Buuse

(2010), Vol. 649, pp. 224-228, European journal of pharmacology, Amsterdam, The Netherlands, C1-1

journal article

Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2010), Vol. 97, pp. 293-300, Pharmacology, biochemistry and behavior, Philadelphia, Pa., C1-1

journal article

Oxidative pathways as a drug target for the treatment of autism

K Villagonzalo, S Dodd, O Dean, K Gray, B Tonge, M Berk

(2010), Vol. 14, pp. 1301-1310, Expert opinion on therapeutic targets, London, England, C1-1

journal article

The validity and internal structure of the bipolar depression rating scale (BDRS): data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder

M Berk, S Dodd, O Dean, K Kohlmann, L Berk, G Malhi

(2010), Vol. 22, pp. 237-242, Acta neuropsychiatrica, Oxford, England, C1-1

journal article
2009

Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting

M Berk, S Jeavons, O Dean, S Dodd, K Moss, C Gama, G Malhi

(2009), Vol. 14, pp. 357-360, CNS spectrums, New York, N.Y., C1-1

journal article

Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2009), Vol. 198, pp. 258-262, Behavioural brain research, Amsterdam, The Netherlands, C1-1

journal article

A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.

O Dean, M van den Buuse, A Bush, D Copolov, F Ng, S Dodd, M Berk

(2009), Vol. 16, pp. 2965-2976, Current medicinal chemistry, Schiphol, The Netherlands, C1-1

journal article

Effects of N-acetylcysteine on substance use in bipolar disorder : a randomized placebo controlled clinical trial

M Bernardo, S Dodd, C Gama, D Copolov, O Dean, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush, M Berk

(2009), Vol. 21, pp. 239-245, Acta neuropsychiatrica, Oxford, England, C1-1

journal article
2008

N-acetyl cysteine for depressive symptoms in bipolar disorder - a double blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush

(2008), Vol. 64, pp. 468-475, Biological psychiatry, Philadelphia, Pa., C1-1

journal article

N-Acetyl cysteine as a glutathione precursor for schizophrenia : a double blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological psychiatry, Philadelphia, Pa., C1-1

journal article

Glutathione : a novel treatment target in psychiatry

M Berk, F Ng, O Dean, S Dodd, A Bush

(2008), Vol. 29, pp. 346-351, Trends in pharmacological sciences, London, England, C1-1

journal article

Oxidative stress in psychiatric disorders : evidence base and therapeutic implications

F Ng, M Berk, O Dean, A Bush

(2008), Vol. 11, pp. 851-876, International journal of neuropsychopharmacology, Cambridge, England, C1-1

journal article

N-acetylcysteine for antioxidant therapy : pharmacology and clinical utility

S Dodd, O Dean, D Copolov, G Malhi, M Berk

(2008), Vol. 8, pp. 1955-1962, Expert opinion on biological therapy, London, England, C1-1

journal article

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological Psychiatry, Philadelphia, Pa., C1-1

journal article
2004

A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use

S Jespersen, M Berk, C Van Wyk, O Dean, S Dodd, C Szabo, C Maud

(2004), Vol. 19, pp. 161-164, International clinical psychopharmacology, Philadelphia, Pa., C1-1

journal article

Funded Projects at Deakin

Australian Competitive Grants

The Efficacy of N-acetylcysteine as an Adjunctive Treatment in Bipolar Depression: A Double-blind, Randomised, Placebo-controlled Trial

Prof Michael Berk, A/Prof Olivia Dean, A/Prof Susan Cotton, Dr Seetal Dodd, Prof Gin Malhi, A/Prof Chee Ng

NHMRC Project Grant

  • 2015: $69,545
  • 2014: $169,437
  • 2013: $74,883
  • 2012: $197,858

The Efficacy of N-acetylcysteine as an adjunctive treatment in unipolar depression

Prof Michael Berk, Prof Gin Malhi, Dr Seetal Dodd, A/Prof Olivia Dean

NHMRC Project Grant

  • 2012: $32,725
  • 2011: $48,924

Proof of principle of the inflammatory and oxidative theory of depression: A treatment study

Prof Michael Berk, Dr Andrew Chanen, Ms Susan Harrigan, Christopher Davey, Dr Sarah Hetrick, A/Prof Olivia Dean, Dr Seetal Dodd

NHMRC Project Grant

  • 2018: $20,933
  • 2017: $102,975
  • 2016: $152,181
  • 2015: $110,745
  • 2014: $111,704
  • 2013: $105,227
  • 2012: $26,547

The efficacy of adjunctive Garcinia mangostana Linn. pericarp for bipolar depression: A 24-week double-blind, randomized, placebo-controlled trial.

A/Prof Olivia Dean, Prof Michael Berk, Prof Chee Ng, Dr Seetal Dodd, Prof Malcolm Hopwood, Dr Alyna Turner, Prof Felice Jacka

NHMRC Project Grant

  • 2020: $76,202
  • 2019: $264,142
  • 2018: $342,644
  • 2017: $209,758

Integrated exploration of novel therapies for depression

A/Prof Olivia Dean

NHMRC CDF - Career Development Fellowship

  • 2021: $126,121
  • 2020: $124,380
  • 2019: $122,663
  • 2018: $120,850

The N-ICE trial: A randomised controlled trial of the safety and efficacy of N-Acetyl Cysteine (NAC) as a pharmacotherapy for methamphetamine ('ice'¿) dependence

A/Prof Rebecca McKetin, A/Prof Olivia Dean, Prof Dan Lubman, Prof Paul Dietze, Dr Peter Higgs, Dr Peter Kelly, Dr Alyna Turner, Dr Brendan Quinn, Prof Greg Carter

NHMRC Project Grant

  • 2019: $138,332
  • 2018: $153,853
  • 2017: $71,859

CREDIT: The CRE for the Development of Innovative Therapies for Psychiatric Disorders

Prof Michael Berk, Prof John McGrath, Prof Patrick McGorry, Prof John McNeil, Prof Gin Malhi, Prof Felice Jacka, A/Prof Susan Cotton, Prof Ken Walder, A/Prof Olivia Dean, A/Prof Lana Williams

NHMRC - Centres of Research Excellence

  • 2022: $374,044
  • 2021: $563,659
  • 2020: $576,585
  • 2019: $510,344

Mental Health Australia General Clinical Trial Network (MAGNET)

Prof Michael Berk, Prof Susan Rossell, Dr Paul Fitzgerald, Prof Adrienne O'Neil, Dr Alyna Turner, Prof undefined Rodgers, Prof Cathy Mihalopoulos, Prof Chee Ng, Dr Christopher Davey, Prof Cherrie Galletly, Prof Anthony Harris, Prof Christos Pantelis, Prof Colleen Loo, Prof Daniel Lubman, Prof Dan Siskind, Prof David Forbes, Prof Denise Meyer, Prof Felice Jacka, A/Prof Frances Kay-Lambkin, Prof Gin Malhi, Prof Greg Murray, Prof Helen Christensen, Prof Jayashri Kulkarni, Prof Jerome Sarris, Prof Jim Lagopoulos, Prof John McGrath, Dr Kate Hoy, Prof Katherine Mills, Prof Mark Nelson, Prof Meaghan O'Donnell, Prof Jane Gunn, Dr Michael Millard, Prof Michael Kyrios, Prof Murat Yucel, Prof Nicholas Glozier, Prof Nicholas Martin, A/Prof Olivia Dean, Prof Osvaldo Almeida, A/Prof Philip Batterham, A/Prof Rebecca McKetin, Prof Richard Bryan, Prof Richard Osborne, Dr Samuel Harvey, Prof Sean Hood, Prof Stephen Touyz, Prof Suresh Sundram, Prof Vasso Apostolopoulos, A/Prof Sophia Zoungas, Prof Svetha Venkatesh, Sarah Russell

MRFF Million Minds Mission Grant Opportunity

  • 2022: $2,132,715
  • 2021: $1,478,704

Other Public Sector Funding

Refrigerated Centrifuge and Vortex

Prof Michael Berk, A/Prof Olivia Dean

NHMRC - Equipment Grant (pre 2017)

  • 2015: $8,187

The mental health data-sharing node: HeSANDA

Prof Alison Yung, Prof Peter Vuillermin, Prof Michael Berk, A/Prof Olivia Dean

ARDC Health Studies National Data Asset Program - Australian Research Data Commons

  • 2022: $60,000
  • 2021: $120,000

Industry and Other Funding

Efficacy of N-Acetyl Cysteine in Autism: A double blind, placebo-controlled randomised trial

Prof Michael Berk, Dr Seetal Dodd, A/Prof Olivia Dean, Dr Katherine Gray, Prof Bruce Tonge

Simons Foundation Autism Research Initiative

  • 2013: $143,821
  • 2012: $119,640

The Efficacy of Minocycline as an Adjunctive Treatment in Unipolar Depression: A Pilot Study

A/Prof Olivia Dean

Australasian Society for Bipolar and Depressive Disorders Ltd

  • 2014: $10,000
  • 2013: $10,000
  • 2012: $10,000

The efficacy of minocycline as an adjunctive therapy for unipolar depression: A pilot study.

A/Prof Olivia Dean

NARSAD - Young Investigator Award

  • 2014: $35,973
  • 2013: $13,966

The efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for the treatment of Schizophrenia: A double-blind, randomized, placebo controlled trial.

Prof Michael Berk, Dr Seetal Dodd, A/Prof Olivia Dean, Dr Alyna Turner, A/Prof Susan Cotton, Prof John McGrath, Dr Frances Dark

SMRI - Treatment Trials - Stanley Medical Research Institute

  • 2021: $117,491
  • 2019: $96,709
  • 2018: $167,831
  • 2017: $363,170
  • 2016: $239,559

Exploring inflammation in depression ¿ Minocycline compared with N-acetyl cysteine.

A/Prof Olivia Dean

Australasian Society for Bipolar and Depressive Disorders Ltd

  • 2017: $10,000
  • 2016: $20,000

The efficacy of adjunctive Garcinia mangostana linn (mangosteen) pericarp for bipolar depression: A 24-week double-blind, randomised, placebo controlled trial

A/Prof Olivia Dean, Dr Melanie Ashton

Australasian Society for Bipolar and Depressive Disorders Ltd

  • 2017: $4,250
  • 2016: $30,000

The efficacy of adjunctive Garcinia mangostana linn (mangosteen) pericarp for bipolar depression: A 24-week double-blind, randomised, placebo controlled trial

A/Prof Olivia Dean, Prof Michael Berk, Dr Melanie Ashton

Australian Rotary Health - Ian Parker Bipolar Fund Scholarship

  • 2019: $15,750
  • 2018: $17,000
  • 2017: $13,136
  • 2016: $3,863

Can we reduce tobacco smoking using N-acetylcysteine as a cessation treatment?

Prof Michael Berk, Dr Seetal Dodd, A/Prof Olivia Dean

Harry Windsor Research Grant

  • 2018: $25,000
  • 2017: $25,000

Trisno Family Postdoctoral Mental Health Research Fellowship

A/Prof Olivia Dean

Trisno Family Fellowship

  • 2022: $30,000
  • 2021: $30,000
  • 2019: $30,000

"Resuming Employment after Stroke: Enhancement through Telecoordination" - RESET Rural Expansion

Dr Alyna Turner, A/Prof Olivia Dean, Dr Alison Kennedy, Dr Mohammadreza Mohebbi, Dr Lan Gao

Stroke Foundation Research Grant

  • 2021: $74,945

A Listening and Learning Healthcare System approach to improve outcomes for acute-care mental health consumers in the Barwon-Southwest Victoria Region.

Prof Anna Peeters, Prof Steven Allender, Prof Sharon Brennan-Olsen, Prof Michael Berk, A/Prof Olivia Dean, Prof Felice Jacka, Prof Adrienne O'Neil, A/Prof Melissa O'Shea, Prof Rajesh Vasa, A/Prof Michael Johnstone, A/Prof Martin Hensher, Dr Josh Hayward, Dr Elijah Marangu, Prof Alison Hutchinson, Dr Mary Lou Chatterton, Miss Sally Buchanan-Hagen

Western Alliance

  • 2021: $118,568

Other Funding Sources

Snijders Labs EvoSafe VF475-86 Upright Freezer - Olivia Dean

A/Prof Olivia Dean

NHMRC - Equipment Grant - Not R&D income countable (2017-current)

  • 2021: $22,516

Supervisions

Principal Supervisor
2019

Melanie Ashton

Thesis entitled: Exploring factors that contribute to treatment response in bipolar depression

Doctor of Philosophy (Medicine), School of Medicine

Associate Supervisor
2021

Lauren Arancini

Thesis entitled: Predictors of Successful Tobacco Smoking Cessation

Doctor of Philosophy (Medicine), School of Medicine

Bianca Kavanagh

Thesis entitled: Impact of Personality Disorder on Health, Functioning, and Treatment Outcomes

Doctor of Philosophy (Medicine), School of Medicine

2020

Declan Bourke

Thesis entitled: Predictors and moderators of treatment efficacy for childhood disruptive behaviours

Doctor of Psychology (Clinical), School of Psychology

2018

David Robert Skvarc

Thesis entitled: The Post-Anaesthesia N-Acetyl-Cysteine Cognitive Evaluation (PANACEA) trial

Doctor of Philosophy (Psychology), School of Psychology

2017

Kyoko Hasebe

Thesis entitled: Investigating Neurobiological Mechanisms Linking Depression and Inflammation

Doctor of Philosophy (Medicine), School of Medicine